文献速递前列腺癌

低危前列腺癌中度大分割放疗的放疗技术与结局:RTOG 0415 二次分析

Radiation technique and outcomes following moderately hypofractionated treatment of low risk prostate cancer: a secondary analysis of RTOG 0415.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2023-02-27

本研究为 RTOG 0415 III 期非劣效试验的二次分析,1079 例低危前列腺癌患者接受中度大分割放疗(MHRT)或常规分割放疗,按放疗技术分层,中位随访 5.8 年。结果显示放疗技术(IMRT 与 3D-CRT)与无生化复发生存、总生存及急性和晚期毒性均无显著差异。

要点

  • 放疗技术(IMRT 与 3D-CRT)与低危前列腺癌 MHRT 后的临床结局无关。
  • MHRT 患者中 3D-CRT 与 IMRT 的晚期泌尿生殖毒性分布不同,但≥2 级晚期泌尿生殖或胃肠道毒性无差异。
  • RTOG 0415 初始发表所示 MHRT 较常规分割放疗增加的晚期泌尿生殖和胃肠道毒性,似乎与 3D-CRT 技术无关。

核心结论

  • 放疗技术未影响低危前列腺癌 MHRT 后的临床结局。
  • 尽管 MHRT 患者中 IMRT 与 3D-CRT 的晚期泌尿生殖毒性分布不同,但≥2 级晚期泌尿生殖或胃肠道毒性及患者报告毒性无差异。
  • RTOG 0415 初始发表所示 MHRT 较常规分割放疗增加的晚期泌尿生殖和胃肠道毒性,似乎与 3D-CRT 治疗技术无关。

研究设计与样本

  • RTOG 0415 为 III 期非劣效试验,将低危前列腺癌患者随机分配至 MHRT 或常规分割放疗,并按放疗技术分层。
  • 本分析为二次分析,比较 IMRT 与 3D-CRT 的总生存(OS)、无生化复发生存(BRFS)及基于 EPIC 评分和 CTCAE 的毒性差异。
  • 1079 例患者接受了分配干预,中位随访 5.8 年;79.1% 的患者接受 IMRT,放疗技术在两组间均衡。

主要发现

  • 在所有患者中,放疗技术与 BRFS、OS 及急性和晚期毒性发生率均无显著差异。
  • 在完成 MHRT 的患者中,3D-CRT 与 IMRT 的晚期泌尿生殖毒性分布存在差异,但≥2 级晚期泌尿生殖或胃肠道毒性无差异。
  • 按放疗技术和分割方式分层,放疗后 EPIC 泌尿和肠道评分的临床最小重要差异(MCID)均无显著差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: While moderately hypofractionated radiotherapy (MHRT) for prostate cancer (PC) is commonly delivered by intensity modulated radiation therapy, IMRT has not been prospectively compared to three-dimensional conformal radiotherapy (3D-CRT) in this context. We conducted a secondary analysis of the phase III RTOG 0415 trial comparing survival and toxicity outcomes for low-risk PC following MHRT with IMRT versus 3D-CRT. METHODS: RTOG 0415 was a phase III, non-inferiority trial randomizing low-risk PC patients to either MHRT or conventionally fractionated radiation with stratification by RT technique. A secondary analysis for differences in overall survival (OS), biochemical recurrence free survival (BRFS), or toxicity by EPIC scores and Common Terminology Criteria for Adverse Events (CTCAE) was performed. RESULTS: 1079 patients received the allocated intervention with a median follow up of 5.8 years. 79.1% of patients were treated with IMRT and radiation technique was balanced between arms. Across all patients, RT technique was not associated with significant differences in BRFS, OS, or rates of acute and late toxicities. For patients completing MHRT, there was a difference in the late GU toxicity distribution between 3D-CRT and IMRT but no difference in late grade 2 or greater GU or GI toxicity. Stratifying patients by RT technique and fractionation, no significant differences were observed in the minimal clinically important difference (MCID) in EPIC urinary and bowel scores following RT. CONCLUSIONS: RT technique did not impact clinical outcomes following MHRT for low-risk PC. Despite different late GU toxicity distributions in patients treated with MHRT by IMRT or 3D-CRT, there was no difference in late Grade 2 or greater GU or GI toxicity or patient reported toxicity. Increases in late GU and GI toxicity following MHRT compared to CFRT, as demonstrated in the initial publication of RTOG 0415, do not appear related to a 3D-CRT treatment technique.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Carpenter DJ, Salama JK, Lee WR, et al. Radiation technique and outcomes following moderately hypofractionated treatment of low risk prostate cancer: a secondary analysis of RTOG 0415. Prostate Cancer Prostatic Dis. 2023. PMID: 36849728. doi:10.1038/s41391-023-00653-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。